Clinical Implementation Specialist - BMT / CGT

Specialty Pharmacy news roundup: September 2026. Investment, consolidation, distribution agreements, accreditations, executive changes, and more, are happening every day in the specialty pharmacy industry. The following are just a few of the many recent activities during the past month. AOM Infusion plans to acquire PromptCare Infusion, Healthcare Dealflow is the first to report. Neither party has issued a press announcement. AOM Infusion is a leading provider of specialty infusion therapy that is backed by private equity firm Revelstoke Capital Partners. PromptCare Infusion is a Waud Capital Partners-backed national provider of respiratory services and home and alternate site infusion therapies. According to a Massachusetts Health Policy Commission filing, AOM's subsidiary, AOM PC Purchaser, LLC, will acquire all equity interests in PromptCare Infusion Buyer, Inc. from PromptCare Intermediate, LP. Flexpoint Ford, a specialist private equity investment firm focused on financial services and adjacent verticals, announced the successful exit of its investment in ArtesRx, LLC to Linden Capital Partners. ArtesRx was established in 2023 by Flexpoint Ford and Dom Meffe, then a Senior Advisor to Flexpoint, to acquire, scale and support pharmacy businesses that serve complex patient populations. Over the course of the partnership, Flexpoint worked closely with management to recruit and build a seasoned executive leadership team, strengthen the Company's sales infrastructure to drive organic growth, and establish an internal M&A engine focused on acquiring complementary businesses. Through this combined organic and acquisition-driven strategy, ArtesRx expanded from three pharmacies predominately serving patients in one state to 16 pharmacies serving patients in 15 states. Bayvrio's approach to pharmacy benefits is reshaping how employers think about the industry. The Bayvrio Pharmacy is the next step in that mission, extending its commitment to best health outcomes directly to patients. The company's grand opening in Tampa was on September 24th. Bayvrio is pairing full-service pharmacy care with critical support, including prior authorization navigation, copay and financial assistance, medication synchronization, and medication therapy management. Biologics was chosen by: * Bristol Myers Squibb as a limited distribution specialty pharmacy provider for ZENBEXUS (iberdomide). This is a newly FDA-approved treatment for certain adults with multiple myeloma who have received prior therapy. * AstraZeneca to be the limited distribution specialty pharmacy provider for ETCAMAH (camizestrant). This drug treats HR+, HER2- advanced breast cancer with a detected ESR1 mutation and is used in combination with a CDK4/6 inhibitor. * Takeda to be part of a limited network of specialty pharmacy providers for MIMRYLO (rusfertide). This therapy treats adults with polycythemia vera (PV). CareMed, owned by PharMerica, has been selected by BioCryst Pharmaceuticals, Inc. as a national pharmacy partner for Orladeyo (berotralstat), an oral treatment used to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older. Seven Bridges/CarePartners Pharmacy announced that Scholar Rock's muscle-targeted treatment for SMA, recently approved by the Food and Drug Administration, is now available at Seven Bridges Specialty/CarePartners Pharmacy as part of a limited distribution network. Longitude Rx and WakeMed are announcing a collaboration focused on advancing and supporting the continued development of the health system's specialty pharmacy program. WakeMed is a nationally recognized, 973-bed not-for-profit health care system founded and based in Raleigh, N.C. Through this collaboration, Longitude Rx will bring deep health system specialty pharmacy expertise to support WakeMed in establishing a strong foundation for its program and positioning it for long term growth. Onco360, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by: * Cycle Pharmaceuticals for Cavhanza (nilotinib) orally disintegrating tablets (ODT), which is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. * Bristol-Myers Squibb for ZENBEXUS (iberdomide), indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.[1] * AstraZeneca for Etcamah(R)(camizestrant), which is indicated for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor (AI) and CDK4/6 inhibitor therapy, based on a US Food and Drug Administration (FDA)-authorized test. * Takeda as an ultra-narrow limited distribution partner for MIMRYLO(TM)(rusfertide), which is a first-of-its kind rare blood cancer treatment in support of patients managing Polycythemia Vera (PV). Priovant Therapeutics selected Orsini and PANTHERx Rare has been selected to dispense LISRAYA (brepocitinib), a newly approved treatment for adults living with dermatomyositis. Shields Health Solutions announced the evolution of its integrated care model, aimed at delivering connected performance across the specialty care continuum. Among the new capabilities now available through its connected model are 340B IQ(TM), designed to simplify the complexities and manual tasks of maintaining a compliant 340B program, and RxTriage(R), which builds a comprehensive and unified intake workflow, while optimizing site of care for the patient and health system.

Longitude Rx has appointed Cora Beth Enzor as chief operating officer. Enzor brings over 20 years of experience building and scaling specialty pharmacy programmes within academic and health system enterprises. She joins from Thyme Care, where she served as vice president of pharmacy operations. Previously, she led Vanderbilt Health Pharmacy Solutions, where she developed health-system-owned specialty pharmacies for multiple organisations. At Longitude Rx, Enzor will oversee enterprise operations, implementation, service delivery, and partner performance as the company expands beyond its founding members. Her priorities include accelerating speed to therapy, standardising operations, and helping health systems manage specialty pharmacy economics. Longitude Rx is a health system-owned specialty pharmacy services organisation established in 2025. Its founding members include Baylor Scott & White Health, Memorial Hermann Health System, Michigan Medicine, Novant Health, and Providence.